Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Telmisartan 80 mg in Healthy Volunteers
NCT03705533Phase 1Completed
- Sponsor
- Pharmtechnology
- Start
- Sep 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telmisartan in hypertension (HTN) (2 arms), sponsored by Pharmtechnology. Primary endpoints: Maximum Plasma Concentration at 72.00 hours and Area Under the Curve to the Last Quantifiable Concentration at 72.00 hours. Started Sep 2018; status: completed.
02
Drugs
telmisartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03705533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03705533.